Wednesday, October 5, 2016

  • 7:00 AM

    Registration Desk Opens, Continental Breakfast Available

  • 8:00 AM - 8:30 AM

    Introductions, Welcome, Tour of conference app

    Cathy Wurzer, Minnesota Public Radio (Moderator)
    Keith Stewart, M.B., Ch.B., Mayo Clinic

  • 8:30 AM - 9:15 AM

    Shaping the Future of Precision Oncology and the Role of the Patient

    Kathy Giusti, M.B.A., Multiple Myeloma Research Foundation

  • 9:15 AM - 10:00 AM

    Towards Precision Medicine

    Euan A. Ashley, M.R.C.P., D.Phil., Stanford

  • 10:00 AM - 10:30 AM

    Break with Refreshments

  • 10:30 AM - 11:15 AM

    Improving Outcomes Through Clinical Implementation of Pharmacogenetics

    Julie A. Johnson, Pharm.D., University of Florida College of Pharmacy

  • 11:15 AM - 12:00 PM

    Title To Be Announced

    Kathy Hudson, Ph.D., National Institutes of Health (NIH)

  • 12:00 PM - 1:00 PM

    Lunch & Presentation

    Teri Manolio, M.D., Ph.D., National Human Genome Research Institute, National Institutes of Health

  • 1:00 PM - 2:30 PM

    This session will give a brief overview of Pharmacogenomic (PGx) concepts as well as an introduction to Mayo Clinic’s PGx Profile Service. The session will also include a case- based approach to explain the significance of PGx testing and its correlation to clinical practice.

  • 1:00 PM - 2:30 PM

    The advent of next generation sequencing and rapid decline in cost has democratized the study of host-microbe interactions. The terabytes of data generated as a result will have potential impact on human health. In this session, we will focus on the clinical applications of next generation sequencing technology and how it has the ability to transform clinical practice. Applications of this new technology include microbial identification, bacterial resistance and virulence profiling, hospital infection surveillance, and diagnosis of hitherto undiagnosed infections, just to name a few. As we face this new friend, it is important to understand both the challenges and benefits that lie ahead of us.

  • 1:00 PM - 2:30 PM

    New genomic technologies are being developed that have the capability of totally transforming clinical practice. Much of what has been driving this has been advances in DNA sequencing, but there are other technologies that could also drive dramatic advances in the clinic. During this session, some of the most exciting, novel, potentially transformative applications will be discussed, including advances in NGS platforM.S., mate pair NGS, gene editing, and genome-based wellness as a lifelong health resource.

    • NGS PlatforM.S.- Where We Are and Where We’re Going David Smith, Ph.D. (Moderator)
    • Mate Pair and Personalized Genomic Management of Glioma Patients Robert Jenkins, M.D.
    • Gene Editing/CRISPR-Cas9 as Powerful Clinical Tools David Bauer, M.D., Ph.D.
    • How to Utilize Genome Tools to Better Inform Patient Wellness Michael Schmidt
  • 1:00 PM - 2:30 PM

    Concurrent Session 1D To Be Announced

  • 2:30 AM - 2:45 AM

    Break with Refreshments

  • 2:45 PM - 4:15 PM

    This session will describe how advances in genetic testing have transformed the Medicial Genetics practice while also introducing unforeseen issues. Common disease testing, pre-natal diagnostics and rare disease testing will be discussed in this session.

  • 2:45 PM - 4:15 PM

    As pharmacogenomic testing becomes more prevalent in our healthcare setting, enabled by lower costs and more clinical applications, mechanisM.S. in medical systeM.S. and decision support tools are being constructed to allow wide scale pre-emptive PGx testing. This session examines some of the ethical challenges and social concerns that this testing may unearth.

  • 2:45 PM - 4:15 PM

    One major challenge currently facing the field clinical genomics is the interpretation of variants of uncertain significance and the discernment of their role, if any, in the etiology of a patient’s condition. This is being addressed in several ways, including improving in silico predictions of pathogenicity, protein modeling to better describe the impact of a non-synonymous variant on protein structure and function, as well as, the creating highly curated clinical sequencing databases to enable the identification of variant to phenotype associations. This session will explore the use of laboratory-based functional genomics and disease modeling to characterize the impact VUSs on protein function and disease. The speakers are all engaged in functional studies associated with large clinical/academic sequencing centers and have built prograM.S. to support interpretation of uncertain findings.

    • Eric Klee, Mayo Clinic, Rochester, MN (Moderator)
    • Karl Clark, Ph.D.
    • Jeremy Prokop, Ph.D.
    • Additional Speaker To Be Announced
  • 2:45 PM - 4:15 PM

    Speakers from both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group Pharmacogenetic (DPWG) gather to discuss key principles in implementing pharmacogenomics into the clinical practice. As both CPIC and DPWG will illustrate, a key part of the process is guideline development as well as the use of informatics.

    Incorporating the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines into Clinical Practice and the Electronic Health Record

    Kelly E. Caudle, Pharm.D., Ph.D., B.C.P.S.

    Informatics to Implement Genetic Tests in the Medical Record

    Robert R. Freimuth, Ph.D.

    Incorporating the Dutch Pharmacogenetics Working Group Pharmacogenetic Guidelines into Clinical Practice and the Electronic Health Record

    Jesse Swen, Ph.D., Pharm.D.

  • 4:15 PM - 4:30 PM


  • 4:30 PM - 5:15 PM

    To Use or Not to Use:  Clinical Application of Genetic Risk Scores in Age-Related Macular Degeneration

    Jonathan L. Haines, Ph.D., Case Western Reserve University

  • 5:15 PM - 7:15 PM

    Poster/Welcome Reception, Light Hors d’ Oeuvres and Beverages Available

Thursday, October 6, 2016

  • 7:00 AM

    Registration Desk Opens, Continental Breakfast Available

  • 8:00 AM - 8:15 AM


  • 8:15 AM - 9:00 AM

    The 100,000 Genomes Project

    Mark Caulfield, FMedSci, Genomics England

  • 9:00 AM - 9:45 AM

    Genomes, Autism, and More Genomes

    Stephen W. Scherer, Ph.D., DSc, University of Toronto McLaughlin Centre & Centre for Applied Genomics at SickKids

  • 9:45 AM - 10:15 AM

    Break with Refreshments

  • 10:15 AM - 11:45 AM

    This session is a guided tour through how to discuss initial testing and deliver testing results for the medical professional. Genetic counselors are essential to genomic care delivery and will review clinical experience with cancer testing discussions as well as whole exome sequencing.

  • 10:15 AM - 11:45 AM

    In this session, speakers from both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group Pharmacogenetic (DPWG) converge again to present examples of how pharmacogenomics has been implemented into the practice.

    • Making Actionable Pharmacogenomics Data and Effective Treatment Optimization Accessible to Every EU citizen - EU U-PGx project and Trial
      • Moderator: Henk-Jan Guchelaar, Pharm.D., Ph.D.
    • Implementing Pharmacogenetics within a Multi-Site Healthcare System
      • Peter Hulick, M.D.
    • National Tumor Sequencing Research Project
  • 10:15 AM - 11:45 AM

    This session focuses on the advances in technology and methods in microbiome research and their application in improving human health. We will learn about novel methods of predicting and testing the function of bacteria within our gut and their application using synthetic biology to develop the next generation probiotics.

  • 10:15 AM - 11:45 AM

    Panel-based targeted NGS testing for inherited disorders is now well-established clinically and the diagnostic benefits of this type of testing are widely appreciated. Cancer NGS panels are also known to be of benefit clinically and are in fairly widespread use, but the specific advantages to individualized cancer management may not be well-understood by many. In this session, experienced individuals will discuss the mainly unchartered territory of more novel approaches for NGS-based testing including virtual panels from whole-exome as well as whole genome sequencing. We will further highlight the exciting example of NGS testing for colorectal cancer and how this is already changing therapy decisions and personalized patient management.

  • 11:45 AM - 12:45 PM


  • 12:45 PM - 2:15 PM

    This session will demonstrate the power of genetics and genomics in the clinic by showing how patient care has been impacted and discoveries have been made to improve the quality of patient care.

  • 12:45 PM - 2:15 PM

    In this session experts in the field will present on the current status of NGS approaches to better delineate the predictive value of genomics in health including direct consumer genomics.

  • 12:45 PM - 2:15 PM

    This session will focus on the application of genomics in the care of cancer patients. Ongoing efforts and results will be discussed in the context of the applicability of the investigators experiences to chart a course for the growing role of genomics in cancer management. Topics covered will include genomic predictors of response to immunotherapy, genomically driven clinical trial design, model systems for laboratory testing of genomic hypotheses, challenges to the clinical application of genomic testing, and strategies for maximizing the clinical benefit of testing.

    • Moderator: Robert R. McWilliams, M.D.
    • Genomics in Immunotherapy
      Roxana S. Dronca, M.D.
    • Melanoma Genomically Enabled Medicine Stand Up to Cancer Study
      Aleksandar Sekulic, M.D., Ph.D.
    • Lessons and Results from the Mayo Clinic Genomic Oncology Service Line
      Alan H. Bryce, M.D.
  • 12:45 PM - 2:15 PM

    Epigenomics is a rapidly emerging scientific discipline which seeks to define how gene transcription and genome activity are regulated in health and disease including cancer. Once considered undruggable, transcriptional and epigenetic mechanisms including “writers”, “readers” and “erasers” of DNA and histone marks are now important targets of drug development, with an ever-increasing number of compounds entering clinical trials. In this session, scientists from the pharmaceutical industry will review emerging epigenetic drug targets, promising new agents in the drug development pipeline, advances in the understanding of these agents’ mechanisms-of-action and experience from ongoing clinical trials.

    • Moderator: Grzegorz S. Nowakowski, M.D., Mayo Clinic
    • Robert J. Sims, III, Constellation Pharmaceuticals
    • Anita K. Gandhi, Celgene Orp.M
    • Thomas Witzig, M.D. Mayo Clinic
  • 2:15 PM - 2:30 PM

    Break with Refreshments

  • 2:30 PM - 3:15 PM

    Marshall Summar, M.D.

  • 3:15 PM - 4:00 PM

    Systems Medicine and P4 Medicine: Transforming Healthcare Through Wellness

    LeRoy Hood, M.D., Ph.D.

  • 4:00 PM - 4:45 PM

    Consumer Genomics Panel Discussion

    LeRoy Hood, M.D., Ph.D.
    Justin Kao
    Additional Panel Members to be Announced

  • 4:45 PM - 5:00 PM


  • Stay for our Friday Workshops! Click here for more information.

Friday, October 7, 2016

  • 8:00 AM - 5:00 AM

    Geneticon Upper Midwest Clinical Genetics

  • 7:00 AM - 8:00 AM

    Continental Breakfast

  • 7:00 AM - 8:00 AM

    Epigenomics and Microbiome Poster Session

    Click here for abstract submission information.

  • 8:00 AM - 12:30 PM

    Workshop Sessions with a Break

  • 8:00 AM - 12:30 PM

    Learn about the TIGER-Bio biomarker development pipeline. Many tumors have multiple mutations, and it is often not clear which mutation or coM.B.ination of mutations is most critical. TIGER-Bio uses multiple genetic profiling platforM.S., integrates bioinformatic analysis within and across patient data sets, validates biomarker targets for test development, and uses interpretive tools to synthesize and present complex data into easy to understand reports.

  • 8:00 AM - 12:30 PM

    Epigenomics Epigenomics: Bridging the Translational Gap

  • 8:00 AM - 12:30 PM


  • 8:00 AM - 12:30 PM

    After participating in this workshop, participants will be better equipped to implement pharmacogenomics in a variety of health care settings. They will understand how to use PGx guidelines to facilitate implementation of pharmacogenomics testing.

    Speakers with experience leading the implementation of pharmacogenomics will provide practical guidance on a range of topics, including forming a team, selecting a testing platform, drug/gene selection, informatics, and economic aspects.


    Introductions & Welcome

    Set the Stage – Background

    What Genes to Implement and How CPIC Prioritizes Gene/Drug Pairs
    Kelly E. Caudle, Pharm.D., Ph.D.
    Testing Options: Pre-Emptive vs Reactive
    Stuart Scott, Ph.D.
    DPYD testing: Implementation in Routine Clinical Care
    Henk-Jan Guchelaar, Pharm.D., Ph.D.
    Panel Discussion
    Curated Questions for discussion from the moderator, each speaker answers, as well as questions from the audience

    Clinical and Research Application

    Education-Clinician and Patient
    Kelly E. Caudle, Pharm.D., Ph.D.
    PGx: A Next Step Into the Future
    Magnus Ingelam-Sundberg, Ph.D., MSc. Med.
    Panel Discussion
    Curated Questions for discussion from the moderator, each speaker answers, as well as questions from the audience
    Break with Refreshments


    Organization of a Clinical PGx Service and its Dilemmas
    Jesse Swen, Pharm.D. Ph.D.
    Hospital Wide Iimplementation vs Implementation to Specialty Groups Only (e.g. cardiology, psychiatry)
    Peter Hulick, M.D.
    Cost/reimbursement and PGx
    Stuart Scott, Ph.D.
    Panel Discussion
    Curated Questions for discussion from the moderator, each speaker answers, as well as questions from the audience
    Closing Comments